Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain [...]
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain
Sesen Bio reports progress with regulators as it preps for [...]
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes
Investors take root in Aspen Neuroscience’s customized cell therapy as [...]
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of [...]
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
With Sarepta in its sights, PepGen prices IPO to fund [...]
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelm
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data [...]
Orion aims to challenge Vertex with new pain management licensing deal
Orion aims to challenge Vertex with new pain management licensing [...]
After layoffs, BridgeBio turns to dealmaking for up to 6 drugs
After layoffs, BridgeBio turns to dealmaking for up to 6 [...]
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blunder
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul [...]
Intellia puts pedal to the metal as 3 new candidates prepped for clinic
Intellia puts pedal to the metal as 3 new candidates [...]